Molecular targetting therapy based on regulation of HER2 protein in advanced gastro-intestinal cancers

在本研究中，我们阐明了基于HER2蛋白调控的生物治疗在胃肠癌患者中应用的可能性。(A)回顾临床病理研究：HER2蛋白的过度表达与组织学类型和肝转移有关，是高分化胃癌患者的预后因素。(B)体外研究：表达HER2蛋白的胃癌细胞株NCI-N87的细胞生长被抗HER2抗体抑制。(C)体内研究：抗HER2抗体抑制NCI-N87皮下移植瘤的生长。这些结果表明，利用抗HER2蛋白的单抗治疗高分化胃癌是一种潜在的复发策略，其应用可以通过检测切除的原发肿瘤中HER2的表达状况来决定。

In this study, we have clarified the possibility of clinical application of a biotherapy based on regulation of HER2 protein in patients with gastro-intestinal cancer.(A)Retrospective clinico-pathological study :Overexpression of HER2 protein was associated with histologic type and liver metastasis, and was a prognostic factor in patients with Well-differentiated gastric cancer.(B)In vitro study :Cell growth of gastric cancer cell line, NCI-N87, expressing HER2 protein, was supressed by anti-HER2 antibody.(C)In vivo study :Tumor growth of NCI-N87 in subcutaneous inplantation was supressed by anti-HER2 antibody. These results suggested that A new therapy using a monoclonal antibody against HER2 protein was a potential candidate for a strategy of recurrence of well-differentiated gastric cancer, and its application could be decided by examining the status of HER2 expression of resected primary tumor.